With the current energy crisis that many European countries are suffering, all the players, states, companies and individuals, are searching for new sources of energy at lower costs. At the same time, sustainability and the environmental compromise are becoming one of the axis of corporate activity focusing in achieving neutral-emission goals. In this context, it is worth discussing Power Purchase Agreements (PPAs) which are understood as long-term contracts under which a business agrees to purchase electricity directly from a renewable energy generator. This type of agreement originated over a decade ago in the United States and, since then, these contracts had grown exponentially from a 0.1 GW in 2010 to 23.7 GW in 2020 and had spread across all the continents.
In the process of data collection, the personal data protection system imposes a relative ban on automated decision-making on controllers (Article 22 of the GDPR), the obligation to take into account data protection by design (Article 25 section 1 of the GDPR) and default data protection (Article 25 section 2 of the GDPR), as well as the need to carry out an assessment of the effects of processing for data protection (data protection impact assessment – art. 35 GDPR). The Data Protection Regulation serves protective purposes, which is to ensure the protection of the rights and freedoms of data subjects in connection with the processing of their personal data, taking into account, however, the principles of data protection regulated in art. 5 of the GDPR, especially reliability and transparency, data minimization and the risk-based mechanism approach.
Under the essence of data protection by design within the meaning of Art. 25 of the GDPR, the controller is obliged to take into account the protection of personal data already at the design stage of a specific solution, service or artificial intelligence system. This is to ensure, among other things, that the protection of personal data will become an immanent element of each project already at the stage of creation.
A drug in a disposable dispenser as a slimming agent – is it legal?
Press controversies related to the use of modern drugs created for the treatment of chronic diseases for procedures with the use of their side effects raise a number of legal problems related to the legality of using such medicinal products for non-dedicated procedures with the use of side effects of the medicinal substance.
Legal assessment on the example of press releases about the use of diabetes drugs, such Ozempic for slimming. Regulatory issues between the drug law and the law of medical devices.
On 5 April 2023 KIEŁTYKA GŁADKOWSKI KG LEGAL will participate in the conference “Longevity Biotech: Investing in a healthier future”. As part of its life science specialisation, our biotech and pharma lawyers offer comprehensive legal services to its clients in many areas of law, including extensive legal services to companies operating in the longevity biotech sector and biotech companies engaged in life extension and human health. Within this specialism our law firm offers assistance in respect of trademark protection and patent issues, regulatory law, certification, contractual, and litigation and arbitration issues. At KG Legal, we know that a key role in the biotechnology sector is innovation and responsiveness to changing market needs. Therefore, we offer our clients a proactive approach, flexibility and efficiency in action. All these qualities of our firm make us recognized as one of the leading law firms in Poland and the world, especially in the field of cross-border specialization and knowledge. As a result, our firm is regularly recommended by international rankings such as the Legal 500.
